My career has been within the academic world of neuromuscular disease and electrodiagnostic medicine. My focus is in disorders of neuromuscular transmission including diagnosis, management and their immune abnormalities with the goal of bringing novel therapeutic agents to the bedside. Most recently, I have been involved in the clinical trials development of complement and FcRn inhibitors in the treatment of autoimmune myasthenia gravis leading to the first 3 drugs ever approved by the FDA for this disease. We maintain extensive clinical and physiological data on nearly 1450 patients with myasthenia gravis.
